Arctoris Acquires Eli Lilly’s Automated Life Sciences Studio to Expand Ulysses Drug Discovery Platform
Arctoris
Fully Automatic Drug Discovery Service Provider
▲October 26-27, Chengdu
China Clinical Trials Industry Development ConferenceClick for FreeRegistration
Note:This article does not constitute any investment opinions or suggestions., subject to official/company announcements;This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Reproduction of any article requires authorization.
Data from Pharma Intelligence Cloud (www.pharnexcloud.com) shows:On September 12, 2024, Eli Lilly sold the majority stake of its automated laboratory, Life Sciences Studio, located in San Diego, to Arctoris, a CRO company headquartered in Oxford. In 2017, Eli Lilly invested approximately $90 million to establish Life Sciences Studio. Previously, Strateos operated and maintained the lab for Eli Lilly, which spans an area of about 11,500 square feet. Arctoris stated that it will continue to expand robotic automation modules, automated BSL-2 cell biology modules, and increase compound storage capacity to 4 million compounds. This is a complementary asset collaboration.
From AI-powered drug screening to being synthesized in automated laboratories, followed by a series of biochemical, cellular, pharmacological, and pharmacokinetic tests to verify molecular activity and drug-likeness, and continuously optimizing molecular design through model iteration,Combination of Dry and WetMay be a better ideal type for new drug development.
Arctoris was first established in 2016. It is reported to be the first company in the global market to provide a fully automated drug discovery platform, where robots can perform various tests, while enabling academic institutions and biotechnology companies to remotely monitor experiments in real time. In July 2020, Insilico Medicine, a leading AI pharmaceutical company, announced a technical partnership with Arctoris.
About the Science Studio
The 11,500-square-foot Science Studio, managed by lab automation provider Strateos, was developed by Lilly with a $90 million investment in 2017 to enhance its research presence in San Diego. This state-of-the-art lab seamlessly combined various drug discovery processes into a fully automated platform, encompassing design, synthesis, purification, analysis, sample management, and hypothesis testing.
About Arctoris
Arctoris is a technology-enabled drug discovery services company
headquartered in Oxford, UK and Boston, USA. Arctoris combines its
unique automation platform, Ulysses™, with a world-class team of
seasoned drug hunters to guide and rapidly progress biotech and
pharmaceutical partner drug discovery programs from target to hit, lead,
and candidate. Ulysses™ is capable of supporting diverse experiments
in biochemistry, cell biology, protein sciences, structural biology,
biophysics, data science and informatics. Arctoris’ meticulous approach
of embedding accuracy into every element of the lab process has
significantly improved precision, consistency, scalability, and data
quality, resulting in thousands of successful experiments with superior
results.
Reference:
NMPA/CDE；
Pharnex Cloud Data www.pharnexcloud.com；
FDA/EMA/PMDA；
Relevant companies have publicly disclosed (all images in the text are from the official enterprises unless otherwise stated);
https://www.arctoris.com/；
https://pharma-industry-review.com/arctoris-acquires-eli-lillys-life-science-studio-drug-discovery-automation-lab；
Eli Lilly sells Life Sciences Studio lab to Arctoris, moving automation platform from San Diego to Oxford，https://www.fiercebiotech.com/cro/eli-lilly-sells-science-studio-lab-arctoris-moving-automation-platform-san-diego-oxford；
AI-Driven: Insilico Medicine WRN Inhibitor for the Treatment of High Microsatellite Instability (MSI-H) Cancers; etc.
[About PharmaCircle]
PRHub of PharmaCircle aims to assist biopharmaceutical technology enterprises in brand promotion and business development services. It formulates systematic solutions based on customers' real needs, and communicates the brand information in a straightforward and comprehensible manner through "translation-simplification-contextualization," ensuring public awareness. At the same time, with access to over 1 million vertical users across various traffic channels, it achieves cooperation objectives, helping partners complete a closed-loop marketing service that starts with branding and ends with business development. We have successfully organized dozens of offline biopharmaceutical R&D conferences with a scale of 1,000 participants, covering areas such as small-molecule new drugs, large-molecule new drugs, improved new drugs, and cross-border BD transactions, serving more than a hundred listed/unicorn/biotech/pharmaceutical companies.
